Loading...
•
Dec 31, 2019
Vir Q4 2019 Earnings Report
Vir reported financial results and provided a corporate update.
Key Takeaways
Vir Biotechnology reported a net loss of $63.8 million for the fourth quarter of 2019, with total revenues of $1.0 million and research and development expenses of $52.9 million. The company highlighted its progress in expanding its clinical and preclinical pipeline and collaborations for COVID-19 therapies.
Identified multiple human monoclonal antibody development candidates that neutralize SARS-CoV-2.
Announced collaborations with WuXi Biologics, Biogen, and Alnylam Pharmaceuticals to advance and produce human monoclonal antibodies for potential COVID-19 treatment.
VIR-2218, a hepatitis B virus (HBV)-targeting siRNA, completed Phase 1/2 dosing of all patient cohorts.
VIR-2482, a monoclonal antibody being developed as universal prophylaxis for influenza A, is in an ongoing Phase 1/2 clinical trial.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...